- Home
- ICUCW vs NUTX Comparison
ICUCW vs NUTX Comparison
Compare ICUCW & NUTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICUCW
- NUTX
- Stock Information
- Founded
- ICUCW N/A
- NUTX 2011
- Country
- ICUCW United States
- NUTX United States
- Employees
- ICUCW 19
- NUTX N/A
- Industry
- ICUCW Biotechnology: Pharmaceutical Preparations
- NUTX Retail: Computer Software & Peripheral Equipment
- Sector
- ICUCW Health Care
- NUTX Technology
- Exchange
- ICUCW Nasdaq
- NUTX Nasdaq
- Market Cap
- ICUCW N/A
- NUTX N/A
- IPO Year
- ICUCW 2021
- NUTX N/A
- Fundamental
- Price
- ICUCW $0.03
- NUTX $120.73
- Analyst Decision
- ICUCW
- NUTX Strong Buy
- Analyst Count
- ICUCW 0
- NUTX 2
- Target Price
- ICUCW N/A
- NUTX $80.00
- AVG Volume (30 Days)
- ICUCW N/A
- NUTX 145.4K
- Earning Date
- ICUCW N/A
- NUTX 05-13-2025
- Dividend Yield
- ICUCW N/A
- NUTX N/A
- EPS Growth
- ICUCW N/A
- NUTX N/A
- EPS
- ICUCW N/A
- NUTX 9.71
- Revenue
- ICUCW N/A
- NUTX $479,948,633.00
- Revenue This Year
- ICUCW N/A
- NUTX N/A
- Revenue Next Year
- ICUCW N/A
- NUTX $13.03
- P/E Ratio
- ICUCW N/A
- NUTX $12.41
- Revenue Growth
- ICUCW N/A
- NUTX 93.80
- 52 Week Low
- ICUCW N/A
- NUTX $4.16
- 52 Week High
- ICUCW N/A
- NUTX $152.51
- Technical
- Relative Strength Index (RSI)
- ICUCW N/A
- NUTX 54.70
- Support Level
- ICUCW N/A
- NUTX $112.30
- Resistance Level
- ICUCW N/A
- NUTX $137.00
- Average True Range (ATR)
- ICUCW 0.00
- NUTX 13.21
- MACD
- ICUCW 0.00
- NUTX -3.34
- Stochastic Oscillator
- ICUCW 0.00
- NUTX 38.30
About ICUCW SeaStar Medical Holding Corporation Warrant
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.